How Fibromyalgia Is Diagnosed: The ACR Criteria and What They Mean

Fibromyalgia has a diagnostic framework. This is worth stating at the outset because many patients arrive at a diagnosis after years of being told their tests are normal, their imaging is unremarkable, and there is nothing objectively wrong. The 2016 ACR revised criteria provide a structured, validated method for diagnosing fibromyalgia based on what the patient reports, not on what tests fail to find [1].

The diagnostic delay is real: Arnold and colleagues found a mean time to diagnosis of over two years, with some patients waiting more than a decade [6]. Part of this delay stems from clinician unfamiliarity with the diagnostic criteria. Part stems from the misconception that fibromyalgia is a diagnosis of exclusion, meaning you can only diagnose it after everything else has been ruled out. The 2016 criteria are positive diagnostic criteria: they identify fibromyalgia based on a specific symptom pattern, not on the absence of other findings [5].

The consequences of diagnostic delay are not merely administrative. A person waiting years for a diagnosis is a person without an explanation for their suffering, without a treatment framework, and frequently without validation that their symptoms have a recognizable medical basis. The delay itself becomes a source of distress, and the repeated experience of normal test results, while intended to be reassuring, often communicates the opposite: that the clinician cannot find anything wrong, and therefore perhaps nothing is.

The 2016 ACR Revised Criteria

The current diagnostic criteria use two scales [1]:

The Widespread Pain Index (WPI) asks the patient to identify which of 19 body areas have been painful in the past week. Each area scores 1 point, for a maximum of 19. The 19 areas cover the full body: jaw, shoulder, upper arm, lower arm, hip, upper leg, and lower leg on each side, plus the neck, upper back, lower back, chest, and abdomen.

The Symptom Severity Scale (SSS) rates the severity of three symptoms (fatigue, waking unrefreshed, and cognitive symptoms) on a 0-3 scale each, plus a 0-3 score for the number of additional somatic symptoms (headaches, abdominal pain, depression). The maximum is 12.

A fibromyalgia diagnosis requires one of two combinations: WPI of 7 or higher with SSS of 5 or higher, or WPI of 4-6 with SSS of 9 or higher. The second combination captures patients whose pain is concentrated in fewer body regions but whose overall symptom burden is high: this acknowledges that fibromyalgia is more than a pain condition and that fatigue, cognitive difficulty, and other symptoms contribute meaningfully to disability. Symptoms must have been present at a similar level for at least three months. And a diagnosis of fibromyalgia does not exclude other clinical diagnoses [1].

The shift to patient-reported criteria was deliberate. The WPI and SSS can be completed in a few minutes in a clinical setting, do not require specialized equipment or examination technique, and have been validated across multiple populations. They capture the breadth of the condition in a way that a physical examination focused on tenderness at specific body points could not.

What Happened to the Tender Points

The original 1990 ACR criteria required a clinician to find pain at 11 of 18 specific body points on physical examination [2]. These tender points served the field well for research classification but had significant limitations in clinical practice. The examination was not standardized: how hard different clinicians pressed varied substantially, producing different results for the same patient. The tender points captured pain sensitivity but not the other symptom domains (fatigue, cognitive difficulty, sleep disruption) that define the clinical picture.

There was a deeper conceptual problem as well. The tender points tested for peripheral tenderness, the sensitivity of specific tissue sites to applied pressure. But fibromyalgia is fundamentally a central nervous system condition, driven by changes in how the spinal cord and brain process pain signals. Peripheral tenderness is a consequence of central sensitization, not its cause, and testing for it provided a downstream marker rather than a direct assessment of the underlying mechanism [4].

The 2010 revision by Wolfe and colleagues replaced tender points with the patient-reported WPI and SSS [3]. The 2016 revision refined these scales and clarified that fibromyalgia could be diagnosed alongside other conditions, which the earlier criteria had sometimes been interpreted as prohibiting [1]. This clarification was clinically important: fibromyalgia commonly co-occurs with rheumatoid arthritis, osteoarthritis, lupus, and other conditions, and the presence of one does not exclude the other.

The Diagnostic Workup

A responsible fibromyalgia diagnosis includes a clinical evaluation to rule out conditions that produce similar symptoms. Standard blood tests typically include a complete blood count, thyroid function (hypothyroidism causes fatigue and widespread pain), erythrocyte sedimentation rate and C-reactive protein (to screen for inflammatory conditions), and sometimes vitamin D level and rheumatoid factor. These tests will be normal in fibromyalgia; their purpose is to exclude conditions that require different treatment [4].

The key principle is that these tests serve to identify conditions that would change management, not to prove that fibromyalgia is present. A normal complete blood count does not confirm fibromyalgia; it excludes anemia as a contributor to fatigue. A normal ESR does not confirm fibromyalgia; it makes an active inflammatory process less likely. The diagnosis of fibromyalgia rests on the positive criteria (WPI and SSS), not on the absence of other findings.

Imaging is generally not needed for fibromyalgia diagnosis unless the clinical examination suggests a specific structural condition. Ordering MRIs “to be sure” often produces incidental findings (disk bulges, degenerative changes) that are equally common in people without pain and can lead to unnecessary procedures. For a patient already anxious about the cause of their pain, an incidental imaging finding can become a new source of distress and a misleading explanation that diverts attention from the central sensitization that is actually driving the symptoms.

Fibromyalgia Is Not a Diagnosis of Exclusion

This misconception persists despite being explicitly addressed by the researchers who developed the diagnostic criteria. A diagnosis of exclusion means that you diagnose the condition only after all other possibilities have been eliminated. Fibromyalgia has positive diagnostic criteria: if a patient meets the WPI and SSS thresholds and has had symptoms for three months, they can be diagnosed with fibromyalgia. Other conditions should be assessed for and, if present, diagnosed and treated, but they do not exclude fibromyalgia [5].

This matters because the “exclusion” framing contributes to diagnostic delay. A clinician who believes fibromyalgia can only be diagnosed after exhaustive testing will order more tests, refer to more specialists, and take longer to begin appropriate treatment. The patient meanwhile experiences the delay as confirmation that nobody can figure out what is wrong.

Häuser and Fitzcharles addressed this directly in their review of fibromyalgia myths: the notion that fibromyalgia requires exclusion of all other diagnoses is not supported by the criteria and leads to unnecessary, costly, and psychologically harmful diagnostic odysseys [5]. A reasonable initial workup, the application of the validated criteria, and a clear explanation to the patient is the appropriate standard. It does not require every subspecialist in the hospital.

The Diagnosis as a Starting Point

Receiving a fibromyalgia diagnosis is, for many patients, both a relief and a frustration. The relief comes from having a name for what they are experiencing, a recognized condition with a diagnostic code, treatment options, and a research base. The frustration comes from the fact that the diagnosis identifies a symptom pattern and an underlying mechanism (central sensitization) without pointing to a single, correctable cause.

This is worth understanding clearly. Fibromyalgia is not a disease in the way that a bacterial infection is a disease, with a specific pathogen that can be eliminated. It is a state of the nervous system, a sensitization of pain processing that has become self-maintaining. The diagnosis identifies that state and opens the door to treatments that address it: medications that modulate pain processing, exercise that recalibrates the nervous system’s sensitivity, sleep interventions that interrupt the sleep-pain cycle, and pain neuroscience education that changes how the patient understands their symptoms [4].

The multimodal nature of these treatments is not a limitation; it reflects the multimodal nature of the condition. Central sensitization involves altered pain processing, disrupted sleep, dysregulated stress responses, and changes in how the brain prioritizes threat signals. No single intervention addresses all of these at once, which is why the most effective approaches combine physical, pharmacological, and educational strategies tailored to the individual patient’s most prominent symptom drivers.

What Remains Uncertain

Whether the WPI/SSS criteria capture all patients who would benefit from fibromyalgia-type treatment is debated. Some patients with central sensitization may not meet the current thresholds, particularly if their pain is concentrated in fewer than four body regions. The criteria are also based on self-report, which introduces variability depending on how patients interpret the questions. Whether the criteria perform equally well across different cultural and linguistic contexts is an area with limited research. Finally, while the diagnostic criteria identify a symptom pattern, they do not directly measure the underlying mechanism (central sensitization), and developing diagnostic tools that assess the mechanism rather than the symptoms remains an aspiration rather than a clinical reality.

Getting support for chronic pain. Chronic pain, including fibromyalgia, is a complex medical condition that deserves proper clinical attention. A GP, rheumatologist or pain specialist can help develop a management plan. The American Chronic Pain Association (theacpa.org) and the National Fibromyalgia Association (fmaware.org) have patient resources and practitioner directories.